Edwards Lifesciences Corporatio (EW) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.80
- Estimate
- $0.74
- Surprise
- +8.6%
- Revenue (period 2026-09-30)
- $1.72B
- Score today
- 5.5/10
Revenue source: xbrl.
How the report landed
Edwards Lifesciences Corporatio (EW) beat the $0.74 estimate with adjusted EPS of $0.80 — a clear 8.6% upside surprise.
Coverage in the report window
- Edwards Lifesciences Sees Q4 Adj EPS $0.61-$0.69 vs $0.71 Est; Sees Sales $1.670B-$1.750B vs $1.700B Est — benzinga, 2026-11-04
Where TrendMatrix's rating stands now
TrendMatrix currently rates EW Hold at 5.5/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +8.6% surprise compares with a +3.7% four-quarter average.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.6 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Product: TAVR (74.0%)
- Concentration risk — Geographic: United States (58.0%)
- Analyst target reached - limited upside remaining
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $99.37
- Entry target
- $96.57
- Stop
- $90.97
The stock trades at 59.1× trailing but 29.4× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 77 — a level conventionally read as overbought; gains at these levels often lean on momentum; trading volume is running 1.8× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-11-05 — shown for context, not personalized investment advice.
EW at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $57.22B
- P/E (fwd)
- 29.4
- P/E (ttm)
- 59.1
- 52-week range
- $74.66–$100.25
- Off 52-week high
- 0.9%
- RSI (14)
- 77
- Volume vs avg
- 1.76×
- Score today
- 5.5/10